Closed Loop Medicine Ltd.

Closed Loop Medicine Ltd. focuses on enhancing personalized treatment solutions by integrating dose-optimized drug therapy with digital therapeutics, particularly for chronic disease management. Closed Loop Medicine Ltd. was founded in 2017 and is headquartered in Cambridge, UK.

The company specializes in developing personalized drug plus digital therapy solutions. The founder, Paul Goldsmith, has a background in healthcare innovation. As of October 2021, Closed Loop Medicine raised GBP 13. 45 million in Series A funding, with participation from investors including Ananda Impact Ventures, BGF, and Cambridge Angels Group.

The total amount raised to date is GBP 13. 45 million, with a current company valuation of GBP 33. 841 million. Closed Loop Medicine specializes in integrating dose-optimized drug therapy with digital therapeutics to enhance personalized treatment solutions for patients with chronic diseases.

Their proprietary platform combines pharmacological treatments with digital health tools, improving patient adherence, therapy optimization, and behavioral change. The key product, CLM-IN01, addresses insomnia through a combination of medication and software as a medical device (SaMD), enabling real-time patient monitoring and engagement. Their client base includes pharmaceutical companies, payors, and healthcare providers across the UK and Europe, aimed at improving healthcare delivery systems and patient outcomes. Closed Loop Medicine generates revenue through partnerships and sales of combination products administered under a single prescription.

Their business model involves collaborations with pharmaceutical companies and healthcare providers, facilitating integrated health solutions that enhance patient care. Clients typically pay for access to the platform and flagship products like CLM-IN01, supported by their regulatory-compliant offerings that align with healthcare providers' needs. In October 2021, Closed Loop Medicine Ltd. raised GBP 13.

45 million in Series A funding, co-led by Ananda Impact Ventures and Business Growth Fund, along with participation from Downing Ventures, LifeArc, and Meltwind. The funding will be utilized to finance the development of personalized drug plus digital therapy (DTx) combination products aimed at enhancing outcomes for patients and clinicians through precision dosing. The company plans to expand into new markets, focusing on increasing its presence across Europe by 2023.